November 2025 proved to be one of the most strategically charged months for the pharmaceutical and biotech sector, driven by cross-border collaborations, oncology licensing and engineered platform integrations that will influence both pipeline velocity and commercial scale through 2026. Key global players scaled R&am…
October 2025 turned out to be a blockbuster month of strategic partnerships, billion-dollar acquisitions, and cross-border collaborations redefining how innovation scales in the post-pandemic biotech economy. From antibody-drug conjugates (ADCs) to RNA medicines, obesity drugs, and gene therapies, global giants and a…
The pharmaceutical and biotechnology sectors experienced a highly active September 2025, characterized by strategic licensing agreements, acquisitions, and partnerships across multiple therapeutic areas. Companies focused on portfolio expansion, precision medicine, advanced therapies, and operational optimization, sig…
The global pharmaceutical and biotechnology industry is in a phase of intensified activity, with acquisitions, licensing deals, and strategic alliances reshaping the landscape. Over the past month, major companies have pursued bold moves to strengthen pipelines, scale manufacturing, and accelerate access to next-gener…
Page 2 of 2